Vir Biotechnology, Inc.
Clinical trials sponsored by Vir Biotechnology, Inc., explained in plain language.
-
New hope for tough prostate cancers: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug, VIR-5500, in people with advanced prostate cancer that no longer responds to hormone therapy. The trial will first find a safe dose, then test it alone or with other drugs. About 390 participants will join to see if the drug is safe and sh…
Phase: PHASE1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated May 26, 2026 12:07 UTC
-
New hope for hard-to-treat HER2 cancers? early trial begins.
Disease control Recruiting nowThis early-phase trial tests a new drug called VIR-5818, alone or with another drug (pembrolizumab), in people with advanced HER2-positive cancers that have spread. The main goals are to check safety and find the right dose. About 645 adults with various solid tumors will take pa…
Phase: PHASE1, PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated May 26, 2026 12:02 UTC
-
New hope for Hard-to-Treat cancers: first human trial of VIR-5525 begins
Disease control Recruiting nowThis early-phase study tests a new drug called VIR-5525, alone or with an immunotherapy (pembrolizumab), in adults with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. Up to 450 participants will be enrolled acros…
Phase: PHASE1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated May 26, 2026 08:20 UTC